Aoxing Pharmaceuticals (AXN), IsoRay (ISR), Opko Health (OPK)


Aoxing Pharmaceutical Company, Inc. (NYSE: AXN)

AXN has reversed its near term gains from a recent high of  $3.48 just 2 weeks ago, down to a close of $1.80 as of Friday, June 19. The company had recently received receipt of a license to produce Tilidine HCL Tablets from the China Food and Drug Administration.

Aoxing Pharmaceutical’s Chairman and CEO said, “This approval is the culmination of 12 years of research, development and regulatory activities. Our entry into the market will be a significant break-through in China’s fight to treat pain, and our Tilidine HCL tablets offer a convenient medium for delivery of this drug, which is essential in the fight against pain. Aoxing will be the sole producer of Tilidine HCL tablets in China.”

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People’s Republic of China.  Yahoo! Finance

Low cost trades, higher leverage

IsoRay, Inc. (NYSE: ISR)

On June 17, ISR has announced the successful Evaluation of the company’s quality management system completed by the British Standards Institution, or BSI. ISR undergoes scrupulous audits to maintain its ISO certification in the EU.

ISR CEO Dwight Babcock, noted “Operating in a heavily regulated international environment as we do, it is crucial that IsoRay continues to dedicate a substantial amount of energy and vigilance to our quality systems. It remains a very high priority that IsoRay products and processes pass muster with the most demanding international standards, including ISO 13485.”

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. Yahoo! Finance

Opko Health, Inc. (NYSE: OPK)

OPK has seen a strong move over the past 52 weeks gaining roughly 69% while just in the past month have tacked on nearly 40% in value on increased volume.

Just recently, a form 4 was filed for an insider purchase and according to InsiderTradingReport, Gamma Investments Trust Frost, CEO of Opko Health, Inc. purchased 15,400 shares on Jun 17, 2015. The Insider buying transaction was disclosed on Jun 18, 2015 to the Securities and Exchange Commission. The shares were purchased at $15.35 per share for a total value of $236,415.66.

OPK has also been in the news as it has announced it would be acquiring Bio-Reference Laboratories (NASDAQ: BRLI) for $1.5 billion. OPK plans to utilize BRLI’s marketing and distribution channels to further push the development their prostate cancer drug.

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally.

These buzzing healthcare names are sure to be worth a second look and worthwhile keeping on your watchlist as they are poised to make a mover back higher as new developments materialize.